A Phase 3 interventional study of Celebrex in Osteoarthritis,Knee, sponsored by Pfizer. Completed at 16 sites in Italy. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2008-06-10.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing celecoxib in Osteoarthritis, Knee — 1 open to participants now, 1 under way, none of them phase 3. Celecoxib · Osteoarthritis, Knee.
Among the 14 studies testing celecoxib in Osteoarthritis, Knee, this one is the 8th largest by enrollment, is one of 2 that started in 2002, is one of 2 in phase 3, and was the 1st registered.
3,296 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.
Browse Osteoarthritis, Knee studies →1 of the 14 studies testing celecoxib in Osteoarthritis, Knee is open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 41+
By country, each count listing its studies:
Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 385 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 114 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 216 across the 14 interventional studies. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 14 have an industry lead sponsor. The 8 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
17 studies in Osteoarthritis, Knee by Pfizer: 2 open now, 2 under way, 2 of them phase 3. Of 14 finished, 8 (57%) have results posted.
Among the 17 studies in Osteoarthritis, Knee by Pfizer, this one is the 9th largest by enrollment, is the only one that started in 2002, is one of 8 in phase 3, and was the 1st registered.
Pfizer’s Osteoarthritis, Knee studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing celecoxib in Osteoarthritis, Knee, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 17 in Osteoarthritis, Knee:
This tab as a report to print or save as PDF → With an account.
This is a phase III, multicentre, randomized, double blind, parallel-group, pilot study designed to compare a long term (12 weeks) versus a short term (2 weeks) treatment with celecoxib 200 mg/die in treatment and prevention of new flare in patients with osteoarthritis of the knee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Time elapsing between the last drug administration and a new flare, if any, occurring within a 12 months FU and proportion pts with a new flare
Flare intensity WOMAC OA index Psycho-affective Index Pt's assessment of OA pain (VAS) Pt's & Physician's global assessment disease severity Incidence of total AEs Incidence of GI AEs: Incidence of changes in: hematology, renal function, liver function
The record gives a start of Nov 2002, a primary completion of Mar 2006 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib